Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 15/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.47 |
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | PAK4 | O96013 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706088 | 0.91 | SYK (0.56) | SYKAURKBPTK2JAK3BTK | |
| SCHEMBL1223740 | 0.91 | SYK (0.60) | SYKAURKBPTK2JAK3BTK | |
| Hydrochloric Acid SCHEMBL6313415 | 0.90 | SYK (0.59) | SYKAURKBPTK2JAK3BTK | |
| SCHEMBL31747057 | 0.77 | ADORA3 (0.74) | SYKAURKBPTK2JAK3BTK | |
| Hydrochloric Acid SCHEMBL29369317 | 0.76 | ADORA3 (0.72) | SYKAURKBPTK2JAK3BTK | |
| SCHEMBL18018864 | 0.75 | BTK (0.54) | SYKAURKBPTK2JAK3BTK | |
| SCHEMBL12085334 | 0.75 | JAK3 (0.63) | SYKJAK3BTKPAK4 | |
| SCHEMBL2122034 | 0.74 | JAK3 (0.63) | SYKJAK3BTK | |
| SCHEMBL10127675 | 0.74 | SYK (0.52) | SYKPTK2JAK3BTK | |
| SCHEMBL20776833 | 0.74 | BTK (0.51) | SYKPTK2BTKIGF1RADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190040065-A1 | EGFR Inhibitors and Methods of Treating Disorders | DANA-FARBER CANCER INSTITUTE, INC. | 2019-02-07 | — | — | US | disclosed |
| US-9908884-B2 | EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| EP-2440559-B1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INST INC (US) | 2018-01-10 | — | — | EP | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2440559-A2 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | Dana-Farber Cancer Institute, Inc. (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010129053-A2 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INSTITUTE (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB4 | SYK 542/4885AURKB 773/4885PTK2 226/4885 |
| US-20190040065-A1 | EGFR Inhibitors and Methods of Treating Disorders | EGFR, ERBB2, ERBB4 | SYK 542/4885AURKB 773/4885PTK2 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.